



Article

Novel 2-alkythio-4-chloro-*N*-[imino(heteroaryl)methyl]benzenesulfonamide Derivatives: Synthesis, Molecular Structure, Anticancer Activity and Metabolic Stability

Beata Żołnowska ^{1,*} , Jarosław Sławiński ¹ , Mariusz Belka ², Tomasz Bączek ² , Jarosław Chojnacki ³ and Anna Kawiak ^{4,*}

- ¹ Department of Organic Chemistry, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland; jaroslaw.slawinski@gumed.edu.pl
- ² Department of Pharmaceutical Chemistry, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland; mariusz.belka@gumed.edu.pl (M.B.); tbaczek@gumed.edu.pl (T.B.)
- ³ Department of Inorganic Chemistry, Gdańsk University of Technology, ul. Narutowicza 11/12, 80-233 Gdańsk, Poland; jaroslaw.chojnacki@pg.edu.pl
- ⁴ Department of Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, ul. Abrahamowa 58, 80-307 Gdańsk, Poland
- * Correspondence: beata.zolnowska@gumed.edu.pl (B.Ż.); anna.kawiak@biotech.ug.edu.pl (A.K.)

Abstract: A series of novel 2-alkythio-4-chloro-*N*-[imino-(heteroaryl)methyl]benzenesulfonamide derivatives, **8–24**, were synthesized in the reaction of the *N*-(benzenesulfonyl)cyanamide potassium salts **1–7** with the appropriate mercaptoheterocycles. All the synthesized compounds were evaluated for their anticancer activity in HeLa, HCT-116 and MCF-7 cell lines. The most promising compounds, **11–13**, molecular hybrids containing benzenesulfonamide and imidazole moieties, selectively showed a high cytotoxic effect in HeLa cancer cells (IC₅₀: 6–7 μM) and exhibited about three times less cytotoxicity against the non-tumor cell line HaCaT cells (IC₅₀: 18–20 μM). It was found that the anti-proliferative effects of **11**, **12** and **13** were associated with their ability to induce apoptosis in HeLa cells. The compounds increased the early apoptotic population of cells, elevated the percentage of cells in the sub-G1 phase of the cell cycle and induced apoptosis through caspase activation in HeLa cells. For the most active compounds, susceptibility to undergo first-phase oxidation reactions in human liver microsomes was assessed. The results of the in vitro metabolic stability experiments indicated values of the factor $t_{1/2}$ for **11–13** in the range of 9.1–20.3 min and suggested the hypothetical oxidation of these compounds to sulfenic and subsequently sulfinic acids as metabolites.

Keywords: benzenesulfonamide; imidazole; synthesis; anticancer; apoptosis; metabolic stability; cell cycle flow cytometry analysis



Citation: Żołnowska, B.; Sławiński, J.; Belka, M.; Bączek, T.; Chojnacki, J.; Kawiak, A. Novel 2-alkythio-4-chloro-*N*-[imino(heteroaryl)methyl]benzenesulfonamide Derivatives: Synthesis, Molecular Structure, Anticancer Activity and Metabolic Stability. *Int. J. Mol. Sci.* **2023**, *24*, 9768. <https://doi.org/10.3390/ijms24119768>

Academic Editor: Antonio González-Sarriás

Received: 9 May 2023

Revised: 31 May 2023

Accepted: 2 June 2023

Published: 5 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cancer is a major public health problem and a leading cause of death worldwide which caused nearly 10 million deaths in 2020 [1]. Basic and clinical research are still needed to increase our knowledge about cancer and accelerate progress in the fight against it. Breast, cervical and colorectal cancers are the most common female cancer types worldwide. In women, the incidence rates of breast cancer far exceed those of other cancers in both transitioned (55.9 per 100,000) and transitioning (29.7 per 100,000) countries, followed by those of colorectal cancer (20 per 100,000) in transitioned countries and of cervical cancer (18.8 per 100,000) in transitioning countries [2].

One of the most important strategies in the search for chemotherapeutics is the approach based on combining in one molecule building blocks, fragments of known drugs, leading structures or “hit” structures [3–6]. The conjugation of two pharmacophores into a

single chemical entity called a hybrid aims at achieving a synergistic effect with increased efficacy compared to the starting compounds [7,8]. The pharmacophores can be combined using three basic types of conjugation leading to linked, fused and merged hybrids [9–12]. Among the advantages of the molecular hybrid are higher activity due to its effect on many molecular targets, minimization of drug resistance and side effects, and improvement of the pharmacokinetic properties [13]. From the molecular design point of view, the combination of two pharmacophores into a single molecule represents one of the methods that can be adopted for the synthesis of new anticancer molecules [14].

The United States Food and Drug Administration (FDA) databases reveals the structural importance of nitrogen-based heterocycles in designing pharmaceuticals. Closely 75% of unique small-molecule drugs contain a nitrogen heterocycle [15]. Imidazoles belong to the most frequently appearing nitrogen heterocycles in small-molecule drugs. These ring systems containing two nitrogen atoms influence a wide range of biological activities such as anticancer [16], antibacterial [17], antiviral [18], antiepileptic [19], antitubercular [20] and antifungal activities [21]. Among anticancer imidazoles, nilotinib is known as a second-generation tyrosine kinase inhibitor, widely used in the treatment of Chronic Myeloid Leukemia (CML) [22], and dacarbazine as an alkylating agent exhibiting antitumor activity by DNA methylation in colorectal cancers [23].

1,2,4-Triazoles are attractive targets for research due to a number of biological activities including antimicrobial [24], antifungal [25], anti-inflammatory [26], antitubercular [27], antiviral [28], analgesic [29], and anticancer activities [30]. Literature reports present important chemotherapeutic agents, such as anastrozole, letrozole and vorozole, containing the 1,2,4-triazole ring, which are currently used in the treatment of breast cancer, with a mechanism of action related to aromatase inhibition [31].

Various sulfonamide compounds are used in anticancer therapies (Figure 1). Sulfonamide drugs such as fedratinib (Janus kinase inhibitor) [32], pazopanib (VEGFR growth receptor inhibitor) [33], dabrafenib [34], and vemurafenib (NCT04302025) (which are inhibitors of BRAF V600 protein) lead to the inhibition of cancer cell division. For example, vemurafenib is used as a targeted monotherapy to treat melanoma with a mutation in the BRAF V600 protein [35]. Venetoclax [36], navitoclax [37] and tasisulam [38] are drugs that induce apoptosis.

Apoptosis is a genetically regulated and evolutionarily conserved process with key roles in cellular proliferation and tissue homeostasis [39]. Most anticancer treatments such as chemotherapy, radiotherapy and immunotherapy primarily aim to activate apoptosis; thus, the ability to induce apoptosis in cancer cells is a highly desirable feature of chemotherapeutic agents [40]. The apoptosis-inducing activity of molecules can be investigated through cytometric analysis of DNA fragmentation, loss of mitochondrial membrane potential ($\Delta\psi_m$), phosphatidylserine translocation to the outer leaflet of the cell membrane and caspase activation, as well as by the microscopic observation of morphological changes in tumor cells after treatment with anticancer agents.

In our research, we designed molecular fused hybrids combining a benzenesulfonamide fragment, a heterocyclic system such as imidazole, 1,2,4-triazole and benzimidazole and an imine group as a linker (Figure 1, Formula A). The structures of the compounds were also diversified with substituents at position 2 of benzenesulfonamide to investigate their influence on the hybrids' cytotoxic activity. Screening tests were performed in breast, cervical and colorectal cancer cell lines which represent the most problematic cancer diseases in women according to statistics. A path leading to cancer cell death was investigated by staining cells with Annexin V-PE and 7-AAD and monitoring caspase activation and cell cycle distribution, applying flow cytometry. It is known that achieving the chemical and physical stability of drugs is essential to ensure their quality and safety. We carried out metabolic stability studies to predict the number and types of metabolites formed in a typical test system, i.e., liver microsomes, as well as the potential of the designed compounds as drug candidates.





Figure 1. Imidazole, 1,2,4-triazoles and sulfonamides used in anticancer therapies and structure of the target compounds, Formula A.

2. Results and Discussion

2.1. Chemistry

The starting potassium salts **1–7** were obtained according to the reported procedures for the preparation of N-(benzenesulfonyl)cyanamide potassium salts [41–44]. The novel 2-alkylthio-4-chloro-N-[imino-(heteroaryl)methyl]benzenesulfonamide derivatives **8–24** were synthesized by the reaction of the N-(benzenesulfonyl)cyanamide potassium

salts **1–7** with 1-methyl-1H-imidazole-2-thiol or 4-methyl-4H-1,2,4-triazole-3-thiol or 1H-benzo[d]imidazole-2-thiol using dry toluene or *p*-dioxane as a solvent (Scheme 1).



Scheme 1. Synthesis of the 2-alkylthio-4-chloro-*N*-[imino-(heteroaryl)methyl]benzenesulfonamide derivatives **8–24**. Reagents and conditions: a: 4-toluenesulfonic acid, toluene or *p*-dioxane.

The structures of the final compounds **8–24** were confirmed by IR, ¹H NMR and ¹³C NMR spectroscopy. The IR spectra showed the typical stretching vibration of the NH group at nearly 3300 cm⁻¹ and the presence of two bands at approximately 1630 and 1540 cm⁻¹, corresponding to C=C and C=N stretching. Moreover, the sulfonyl group was identified by bands from S=O stretching (asymmetric and symmetric) at approximately 1370 and 1140 cm⁻¹. The appearance of NH signals at 10.22–11.29 and 8.73–8.83 ppm in the ¹H NMR spectra proved the presence of the SO₂NH and C=NH groups, while singlets at approximately 2.32–2.37, 4.01–4.82, 7.44–7.74 and 7.4–8.06 ppm confirmed a 2-alkylthio-5-methylbenzenesulfonamide scaffold, i.e., the presence of CH₃, CH₂, H-3 and H-6. Moreover, heterocyclic rings attached to a sulfur atom showed specific signals such as doublets at 7.28–7.40 and 7.38–7.59 ppm, describing H-4 and H-5 protons in imidazole, or singlets at 8.73–8.75 ppm, belonging to the H-5 proton in 1,2,4-triazole. Singlets derived from benzimidazole NH protons appeared at 13.58–13.65 ppm.

Compound **10** crystallized in the space group P2₁/c with one molecule in the asymmetric unit. Details on data collection, structure solution and refinement are reported in Table S1 (Supplementary Materials). A molecular view is presented in Figure 2. In the

solid state, the molecule is deprotonated in the sulfonamidic part, and the hydrogen atoms H2a and H2b are located on the amine nitrogen atom N2. They form hydrogen bonds with the neighbor O1 and S3 (for details, see Table S2 in Supplementary Materials). No distinct electron density peak was found in the vicinity of the sulfonamide nitrogen atom N1. Additionally, the CF₃ group was found disordered over two positions, with a site occupation factor of 0.58(2)/0.42(2).




Figure 2. Molecular view of compound **10** showing the atom labelling scheme. Displacement ellipsoids drawn at the 50% probability level; disordered part of the CF₃ group omitted.

2.2. Screening for Anticancer Agents

Compounds **8–24** were evaluated *in vitro* for their cytotoxic effect against three human cancer cell lines, i.e., HeLa (cervical cancer), HCT-116 (colon cancer) and MCF-7 (breast cancer), and the non-tumor cell line HaCaT using the MTT assay after 72 h of incubation. The results of tests are presented in Table 1 as IC₅₀, indicating the concentration required for 50% inhibition of cell viability. Compounds **8–10** and **14–18** are not presented in the Table 1 because of their low potency (IC₅₀ > 100 μM).

Table 1. IC₅₀ values for compounds **11–13** and **19–24** assessed by the MTT test ^a.

Compound	IC ₅₀ [μM]			
	MCF-7	HeLa	HCT-116	HaCaT
11	330 ± 10	6 ± 0.1	11 ± 0.3	18 ± 0.5
12	*	7 ± 0.3	180 ± 4.5	20 ± 1
13	*	6 ± 0.1	73 ± 2	18 ± 0.5
19	82 ± 4	60 ± 3	36 ± 1	NT
20	49 ± 1	43 ± 1	17 ± 0.5	NT
21	62 ± 3	52 ± 1	23 ± 0.2	NT
22	73 ± 2	49 ± 2	27 ± 0.5	NT
23	50 ± 2	57 ± 1	34 ± 0.3	NT
24	56 ± 2	33 ± 1	21 ± 0.6	NT
Cisplatin	3.0 ± 0.1	2.2 ± 0.1	3.8 ± 0.2	7.7 ± 0.2

^a Analysis was performed using the MTT assay after 72 h of incubation. Compounds tested in the concentrations of 1, 10, 25, 50 and 100 μM. Values are expressed as the mean ± SD of at least three independent experiments. * Viability of cell lines in the presence of 100 μM of the tested compounds was approximately 100%. NT—not tested.

As shown in Table 1, the HeLa cell line exhibited the highest susceptibility toward compounds **11–13** (IC₅₀; 6–7 μM) representing a series of 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole derivatives. It is worth noting that the HCT-116 line was noticeably susceptible to the 2-thioxo-2,3-dihydro-1H-benzo[d]imidazole derivatives **19–24** (IC₅₀; 17–36 μM), but the most active compound was the imidazole derivative **11**, with an IC₅₀ value of 11 μM. The MCF-7 cell line provided the weakest response to the cytotoxic effect of the tested compounds, with only the 2-thioxo-2,3-dihydro-1H-benzo[d]imidazole derivatives **19–24**

exhibiting an IC_{50} in the range of 49–82 μM . Unfortunately, the 5-thioxo-4,5-dihydro-1*H*-1,2,4-triazole derivatives **15**–**18** had no effect on cancer cell viability.

We also performed an assay on the non-tumor cell line HaCaT (immortalized human keratinocytes) to assess if the effect of **11**–**13** was selective toward HeLa cells or resulted from a more general toxic activity. The test indicated that the compounds showed selectivity toward cancer cells. Values of IC_{50} in the range of 18–20 μM for HaCaT cells indicated about three times less toxicity than that for HeLa cells. What is important, the cytotoxicity against non-cancerous cells of **11**–**13** was significantly lower than that of the reference drug cisplatin, which is a common drug used for cervical cancer treatment as a cell cycle non-specific drug in the clinic.

2.3. Apoptosis

2.3.1. Cytotoxic Activity

The cytotoxic activity of **11**–**13** was determined in a time-dependent manner with the MTT assay (Figure 3).




Figure 3. Effects of **11**, **12** and **13** on the viability of HeLa cells. HeLa cells were treated with **11** (A), **12** (B) and **13** (C) in the concentration range of 0–20 μM . After 24, 48 and 72 h of incubation, cell viability was assessed with the MTT assay. Values represent the mean \pm SD of three independent experiments.

HeLa cells were treated with **11**, **12** and **13** in the concentration range of 0–20 μM . After 24 h of treatment, the IC_{50} values were not reached by the compounds **11** and **12**, whereas for compound **13**, the IC_{50} value was reached at the concentration of 18 μM . After 48 h, the IC_{50} values for compounds **11**, **12** and **13** were 6, 7 and 6 μM , respectively. Further treatment with the compounds did not increase their cytotoxic activity.

2.3.2. Apoptosis Induction

In order to determine whether the anti-proliferative effects of **11**, **12** and **13** were associated with their ability to induce apoptosis in HeLa cells, the induction of phosphatidylserine externalization by compounds **11**, **12** and **13** was examined by flow cytometric analysis. The cells were treated with 2.5, 5 and 10 μM concentrations of **11**, **12** and **13** for 24 and 48 h and stained with Annexin V-PE and 7-AAD. The results shown in Figure 4 indicated that compounds **11**–**13** induced apoptosis in a concentration- and time-dependent manner. After 24 h of treatment, a significant increase in the early apoptotic population of cells was visible starting from the concentration of 5 μM .




Figure 4. Induction of apoptosis in HeLa cells by **11**, **12** and **13**. Cells were treated with the indicated concentrations of **11** (A), **12** (B) and **13** (C) for 24 h and 48 h. Cells were stained with Annexin V-PE and 7-AAD and analyzed by flow cytometry. Dotplots show early apoptotic (bottom right quadrant), late apoptotic (upper right quadrant), viable (lower left quadrant) and necrotic cell populations (upper left quadrant). Values represent the mean \pm SD of three independent experiments.

A further 24 h incubation increased the percentage of early apoptotic cells at the lowest examined concentration of 2.5 μM . Furthermore, at higher concentrations of **11**, **12** and **13** (5 and 10 μM), a significant increase in cells in the late stage of apoptosis was visible (Figure 5).




Figure 5. Induction of early and late apoptotic cells in the HeLa cell line by **11**, **12** and **13**. Cells were treated with the indicated concentrations of **11** (A), **12** (B) and **13** (C) for 24 h and 48 h. Cells were stained with Annexin V-PE and 7-AAD and analyzed by flow cytometry. Values represent the mean \pm SD of three independent experiments. Data were analyzed by one-way ANOVA with Tukey's post hoc test $p < 0.05$ (*), $p < 0.001$ (**).

These results provide valuable insights into the mechanism of action of compounds **11**, **12** and **13** as potential anti-proliferative agents targeting HeLa cells. The concentration- and time-dependent induction of apoptosis highlighted the effectiveness of these compounds in promoting programmed cell death in the tested cell line.

2.3.3. Caspase Activation

Apoptosis induction was further determined by examining the effects of **11**, **12** and **13** on caspase activation in HeLa cells. Caspase activity induction was determined with the use of the fluorescently labeled caspase inhibitor-FAM-VAD-FMK (a carboxyfluorescein derivative of valylalanylaspatic acid fluoromethyl ketone). The caspase inhibitor binds to active caspases inhibiting their enzymatic activity, thus allowing caspase activity quantification through determining the fluorescent intensity of the bound inhibitor. The results shown in Figure 6 indicated that compounds **11**, **12** and **13** induced caspase activity in HeLa cells in a dose-dependent manner. Increased caspase activation was shown by the increased fluorescence of the caspase inhibitor in the cell population, as indicated in Figure 6. The results showed that compounds **11**, **12** and **13** induced apoptosis through caspase activation in HeLa cells.




Figure 6. Induction of caspase activity in HeLa cells by **11**, **12** and **13**. Cells were treated with the indicated concentrations of **11** (A), **12** (B) and **13** (C) for 24 h, and the enzyme activity was determined by flow cytometry with the use of a caspase inhibitor, FAM-VAD-FMK. Values represent the mean \pm SD of three independent experiments. Data were analyzed by one-way ANOVA with Tukey's post hoc test $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***).

By targeting caspase activation, compounds **11**, **12** and **13** initiate the cascade of events leading to programmed cell death. This observation supports the hypothesis that the anti-proliferative effects of these compounds in HeLa cells are mediated through the induction of apoptosis. The evaluation of caspase activity added valuable insight into the mechanism of action of compounds **11**, **12** and **13**, highlighting their potential as apoptotic inducers in cancer therapy.

2.3.4. Cell Cycle Distribution

The effects of compounds **11**, **12** and **13** on the cell cycle phase distribution of HeLa cells were assessed by flow cytometry. The cells were treated with 5, 7 and 10 μ M concentrations of **11**, **12** and **13** for 48 h and stained with PI. Results presented in Figure 7 showed an increase in the percentage of cells in the sub-G1 phase of the cell cycle upon treatment with compounds **11**, **12** and **13**. Furthermore, the treatment of cells with **12** at the concentrations of 7 and 10 μ M also induced G2/M arrest in HeLa cells. These results pointed to the effects of **11–13** on DNA fragmentation, which could be indicative of internucleosomal DNA fragmentation induction by **11–13**, a hallmark of apoptosis induced by caspase-activated DNase (CAD).




Figure 7. Effects of **11**, **12** and **13** on the sub-G1 population increase in HeLa cells. Cells were treated with the indicated concentrations of **11** (A), **12** (B) and **13** (C) for 48 h, and cell cycle distribution was analyzed using flow cytometry. Values represent the mean \pm SD of three independent experiments. Data were analyzed by one-way ANOVA with Tukey's post hoc test $p < 0.001$ (***)

Taken together, these results indicated that compounds **11**, **12** and **13** exerted their anti-proliferative effects in HeLa cells by inducing DNA fragmentation and potentially triggering apoptosis through the activation of CAD. The cell cycle analysis provided valuable insights into the mechanisms of action of these compounds and their potential as anti-cancer agents.

2.4. In Vitro Metabolic Stability Assay

The three most potent compounds (**11**, **12** **13**) were tested in an in vitro metabolic stability assay. Human liver microsomes along with NADPH were used to assess their susceptibility to undergo first-phase oxidation reactions. The progress of biotransformation was followed by liquid chromatography–mass spectrometry. The results derived from triplicate incubations, expressed as in vitro metabolic half-life ($t_{1/2}$), are shown in Figure 8. In order to support the in vitro results, we performed in silico calculations using the Human Liver Microsome-based model for CYP-mediated oxidations provided by the Xenosite online tool [45].




Figure 8. The summary of the results of the metabolic study. (A) Results from the in vitro metabolic stability assay, presented as mean $t_{1/2}$ from triplicate ($n = 3$) experiments; whiskers represent the standard deviation. (B) Graphical output from in silico Xenosite model; the green color depicts a higher susceptibility to oxidation than the blue color.

In relation to their stability, the compounds could be ordered as **12** > **13** > **11**, with decreasing stability. All substituents in the R^1 position can undergo oxidation, and this occurs for substituents in several positions for 4-chlorophenyl (**11**) and 1-naphthyl (**13**).

Interestingly, in opposition to the Xenosite's results, the derivative bearing a piperonyl moiety (**12**) exhibited the best stability *in vitro* among the studied set of compounds. A detailed survey of possible reasons for this property suggested that another part of the studied molecules can be more important for metabolic stability than the R¹ substituents, thus diminishing their influence.

The most probable hypothesis includes oxidation of the sulfur atom in the thione functionality, resulting in the formation of sulfenic and, subsequently, sulfinic acid. This kind of biotransformation was reported several times in the literature, including in a detailed study of several thioureas and thiones by Henderson and others [46] and also in a paper by Yamazaki et al. for methimazole [47].

3. Materials and Methods

3.1. Synthesis

The melting points were uncorrected and measured using a Thermogalen (Leica, Vienna, Austria) apparatus. The IR spectra were measured on a Thermo Mattson Satellite FTIR spectrometer (Thermo Mattson, Madison, WI, USA) in KBr pellets; the absorption range was 400–4000 cm⁻¹. The ¹H NMR and ¹³C NMR spectra were recorded on a Varian Gemini 200 apparatus or a Varian Unity Plus 500 apparatus (Varian, Palo Alto, CA, USA), as well as on a Bruker Ascend 600 spectrometer (Bruker, Billerica, MA, USA). The chemical shifts are expressed at δ values relative to Me₄Si (TMS) as an internal standard. The apparent resonance multiplicity is described as: s (singlet), br s (broad singlet), d (doublet), t (triplet) and m (multiplet). Elemental analyses were performed on a PerkinElmer 2400 Series II CHN Elemental Analyzer (Perkin Elmer, Shelton, CT, USA), and the results indicated by the symbols of the elements were within $\pm 0.4\%$ of the theoretical values. Thin-layer chromatography (TLC) was performed on Merck Kieselgel 60 F254 plates (Merck, Darmstadt, Germany) and visualized by UV spectroscopy. An HPLC-UV analysis was performed on an Agilent 1260 liquid chromatograph equipped with a VWD detector (Agilent, Santa Clara, CA, USA). A Poroshell EC-C18 column (150 \times 3 mm, 2.7 μ m) (Agilent, Santa Clara, CA, USA) was used at the flow rate of 0.2 mL/min. The injection volume was 5 μ L. Gradient elution was applied as follows: a linear increase of acetonitrile in water from 5% to 100% over 30 min. Detection was performed at 254 nm.

The commercially unavailable *N*-(2-alkylthio-4-chlorobenzenesulfonyl)cyanamide potassium salts were obtained according to the following methods described previously: **1**, **7** [41], **2–3**, **6** [42], **4** [43], **5** [44].

General procedure for the synthesis of 2-alkylthio-4-chloro-N-[imino(heteroaryl)methyl]benzenesulfonamide (8–24)

Method A. A mixture of monopotassium salt (1.5 mmol), *p*-toluenesulfonic acid monohydrate (PTSA) (1.5 mmol) and an appropriate thiol (1.5 mmol) in dry toluene (25 mL) was stirred at reflux for 14–28 h. After cooling to room temperature, an insoluble side product was filtered out. The organic layer was washed with water (2 \times 10 mL), then dried with MgSO₄ and concentrated in vacuum. The residue was dissolved in a hot solvent (acetonitrile for compounds **8** and **12**, benzene for **14**, ethanol for **15**) and left to crystallize at room temperature. The precipitate was collected by filtration and dried.

Method B. A mixture of monopotassium salt (1.5 mmol), PTSA (1.5 mmol) and an appropriate thiol (1.5 mmol) in dry *p*-dioxane (8 mL) was stirred at 105 °C for 4–5 h. After cooling to room temperature, the mixture was concentrated in vacuum to dryness, and the residue was treated with water (20 mL) and stirred using an ultrasonic bath for 5 min. The precipitate was filtered off, dried and crystallized from ethanol (compounds **9** and **16**) or ethanol/acetonitrile mixture (*v/v* = 4:1) (compound **13**).

Method C. A mixture of monopotassium salt (1.5 mmol), PTSA (1.5 mmol) and an appropriate thiol (1.5 mmol) in dry toluene (25 mL) was stirred at reflux for 14 h. After cooling to room temperature, the solid was filtered off and dried. The products were purified by crystallization from acetonitrile (compound **19**).

Method D. A mixture of monopotassium salt (1.5 mmol), PTSA (1.5 mmol) and an appropriate thiol (1.5 mmol) in dry *p*-dioxane (8 mL) was stirred at 105 °C for 1.5–7 h. After cooling to room temperature, an insoluble side product was filtered out, then the filtrate was concentrated in vacuum to dryness, and the residue was treated with water (20 mL) and stirred using an ultrasonic bath for 5 min. The precipitate was filtered off, dried and crystallized from ethanol (compounds **20–24**) or purified by gravity liquid chromatography using silica gel with pore size 60 Å, 220–440 mesh particle size and 35–75 µm particle size (compounds **10, 11, 17, 18**).

2-Benzylthio-4-chloro-*N*-[imino(3-methyl-2-thioxo-2,3-dihydro-1*H*-imidazol-1-yl)methyl]-5-methylbenzenesulfonamide (8)

Method A. Starting from **1** (0.580 g), 1-methyl-1*H*-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in toluene for 14 h, the title compound **8** was obtained (0.485 g, 70%): m.p. 163.4–165 °C dec.; HPLC (purity 98.73%): $t_R = 32.5$ min.; IR (KBr) ν_{\max} 3379, 3207, 3169, 3129 (NH), 3003 (CH_{Ar}), 1637, 1543 (C=C, C=N); 1378, 1137 (SO_2) cm^{-1} ; ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 2.34 (s, 3H, CH_3), 3.53 (s, 3H, $\text{CH}_3\text{-N}$), 4.36 (s, 2H, CH_2), 7.22–7.25 (m, 3H, arom.), 7.30–7.31 (m, 2H, arom.), 7.4 (d, 1H, H-4 imidazole), 7.55 (d, 1H, H-5 imidazole), 7.62 (s, 1H, H-3 arom.), 7.95 (s, 1H, H-6 arom.), 8.82 (s, 1H, NH), 11.29 (s, 1H, SO_2NH) ppm; ^{13}C NMR (150.9 MHz, $\text{DMSO-}d_6$) δ 19.43, 35.02, 36.52, 114.89, 120.89, 127.73, 128.76, 128.85, 129.30, 131.15, 132.82, 136.26, 136.76, 137.97, 138.08, 151.32, 162.20 ppm. Found: C, 48.50; H, 4.10; N, 11.88. Calc. for $\text{C}_{19}\text{H}_{19}\text{ClN}_4\text{O}_2\text{S}_3$: C, 48.86; H, 4.10; N, 12.00%.

4-Chloro-*N*-[imino(3-methyl-2-thioxo-2,3-dihydro-1*H*-imidazol-1-yl)methyl]-5-methyl-2-(3-trifluoromethylbenzylthio)benzenesulfonamide (9)

Method B. Starting from **2** (0.688 g), 1-methyl-1*H*-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in *p*-dioxane for 3.5 h, the title compound **9** was obtained (0.401 g, 50%): m.p. 145.7–146.7 °C; HPLC (purity 98.76%): $t_R = 33.05$ min; IR (KBr) ν_{\max} 3398, 3151, 3120 (NH), 2928 (CH_{Ar}), 1649, 1548 (C=C, C=N), 1329, 1135 (SO_2) cm^{-1} ; ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 2.32 (s, 3H, CH_3), 3.51 (s, 3H, $\text{CH}_3\text{-N}$), 4.48 (s, 2H, CH_2), 7.36 (d, 1H, H-4 imidazole), 7.44 (t, 1H, arom.), 7.53–7.62 (m, 4H, H-5 imidazole and arom.), 7.70 (s, 1H, arom.), 7.95 (s, 1H, H-6 arom.), 8.83 (s, 1H, NH), 11.29 (s, 1H, NHSO_2) ppm; ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 19.64, 35.22, 35.91, 115.10, 121.11, 124.67, 126.20, 129.25, 129.56, 129.80, 130.14, 131.48, 133.38, 133.54, 135.61, 138.31, 138.40, 138.84, 151.50, 162.44 ppm. Found: C, 45.25; H, 3.50; N, 10.76. Calc. for $\text{C}_{20}\text{H}_{18}\text{ClF}_3\text{N}_4\text{O}_2\text{S}_3$: C, 44.90; H, 3.39; N, 10.47%.

4-Chloro-*N*-[imino(3-methyl-2-thioxo-2,3-dihydro-1*H*-imidazol-1-yl)methyl]-5-methyl-2-(4-trifluoromethylbenzylthio)benzenesulfonamide (10)

Method D. Starting from **3** (0.688 g), 1-methyl-1*H*-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in *p*-dioxane for 3 h, after purification on silica gel using $\text{CHCl}_3/\text{MeOH}$ ($v/v = 8:1$) as the eluent, the title compound **10** was obtained (0.369 g, 46%): m.p. 183.3–184.3 °C; HPLC (purity 99.76%): $t_R = 33.15$ min; IR (KBr) ν_{\max} 3385, 3201 (NH), 3033 (CH_{Ar}), 1648, 1534 (C=N, C=C), 1320, 1165 (SO_2) cm^{-1} ; ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 2.33 (s, 3H, CH_3), 3.51 (s, 3H, $\text{CH}_3\text{-N}$), 4.47 (s, 2H, CH_2), 7.38 (d, 1H, H-4 imidazole), 7.51 (d, 2H, arom.), 7.55 (d, 1H, H-5 imidazole), 7.56 (d, 2H, arom.), 7.62 (s, 1H, arom.), 7.95 (s, 1H, arom.), 8.80 (s, 1H, NH), 11.28 (s, 1H, NHSO_2) ppm; ^{13}C NMR (150.9 MHz, $\text{DMSO-}d_6$) δ 19.44, 34.99, 35.79, 114.98, 120.91, 125.63, 125.65, 125.68, 128.92, 131.28, 133.21, 135.49, 138.16, 138.19, 142.13, 151.33, 162.20 ppm. Found: C, 45.40; H, 3.56; N, 11.00. Calc. for $\text{C}_{20}\text{H}_{18}\text{ClF}_3\text{N}_4\text{O}_2\text{S}_3$: C, 45.51; H, 3.62; N, 11.17%.

4-Chloro-*N*-[imino(3-methyl-2-thioxo-2,3-dihydro-1*H*-imidazol-1-yl)methyl]-5-methyl-2-(4-chlorobenzylthio)benzenesulfonamide (11)

Method D. Starting from **4** (0.638 g), 1-methyl-1*H*-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in *p*-dioxane for 4 h, after purification on silica gel using $\text{CHCl}_3/\text{MeOH}$ ($v/v = 8:1$) as the eluent, the title compound **11** was obtained (0.286 g, 38%): m.p. 176.3–177.8 °C; HPLC (purity 99.69%): $t_R = 33.25$ min; IR (KBr) ν_{\max} 3355, 3201 (NH), 3020 (CH_{Ar}), 1633, 1542 (C=N, C=C), 1346, 1138 (SO_2) cm^{-1} ; ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 2.33 (s, 3H, CH_3), 3.52 (s, 3H, $\text{CH}_3\text{-N}$), 4.36 (s, 2H, CH_2), 7.25 (d, $J = 8.3$ Hz, 2H, 4-Cl-Ph arom.), 7.30 (d, $J = 8.3$ Hz, 2H, 4-Cl-Ph arom.), 7.38 (d, 1H, H-

4 imidazole), 7.52 (d, 1H, H-5 imidazole), 7.61 (s, 1H, H-3 arom.), 7.94 (s, 1H, H-6 arom.), 8.79 (s, 1H, NH), 11.28 (s, 1H, NHSO₂) ppm; ¹³C NMR (150.9 MHz, DMSO-*d*₆) δ 19.45, 35.04, 35.67, 114.97, 120.90, 128.80, 128.93, 131.04, 131.21, 132.29, 133.06, 135.80, 136.13, 138.12, 138.16, 151.32, 162.18 ppm. Found: C, 45.46; H, 3.60; N, 11.15. Calc. for C₁₉H₁₈Cl₂N₄O₂S₃: C, 45.51; H, 3.62; N, 11.17%.

4-Chloro-2-(6-chlorobenzo [1,3]dioxol-5-ylmethylthio)-2-N-[imino(3-methyl-2-thioxo-2,3-dihydro-1H-imidazol-1-ylmethyl)]-5-methylbenzenesulfonamide (12)

Method A. Starting from 5 (0.704 g), 1-methyl-1H-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in toluene for 15 h, the title compound 12 was obtained (0.381 g, 47%): m.p. 177–180 °C; HPLC (purity 94.26%): *t*_R = 33.38 min; IR (KBr) *v*_{max} 3341, 3188, 3155, 3133 (NH), 3044 (CH_{Ar}), 1644, 1533 (C=N, C=C), 1343, 1127 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.36 (s, 3H, CH₃), 3.50 (s, 3H, CH₃-N), 4.29 (s, 2H, CH₂), 6.04 (s, 2H, O-CH₂-O), 6.93 (s, 1H, arom.), 6.99 (s, 1H, arom.), 7.33 (d, *J* = 2.7 Hz, 1H, H-4 imidazole), 7.50 (d, *J* = 2.7 Hz, 1H, H-5 imidazole), 7.60 (s, 1H, H-3 arom.), 7.95 (s, 1H, H-6 arom.), 8.77 (s, 1H, NH), 11.27 (s, 1H, SO₂NH) ppm; ¹³C NMR (150.9 MHz, DMSO-*d*₆) δ 19.47, 33.99, 35.10, 102.60, 110.07, 110.59, 114.88, 120.81, 125.63, 127.12, 128.98, 131.19, 133.16, 136.15, 138.18, 138.21, 147.03, 148.08, 151.38, 162.23 ppm. Found: C, 44.00; H, 3.20; N, 9.99. Calc. For C₂₀H₁₈Cl₂N₄O₄S₃: C, 44.04; H, 3.33; N, 10.27%.

4-Chloro-N-[imino(3-methyl-2-thioxo-2,3-dihydro-1H-imidazol-1-yl)methyl]-5-methyl-2-(naphthalen-1-ylmethylthio)benzenesulfonamide (13)

Method B. Starting from 6 (0.661 g), 1-methyl-1H-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in *p*-dioxane for 4 h, the title compound 13 was obtained (0.396 g, 51%): m.p. 197–198 °C; HPLC (purity 98.23%): *t*_R = 33.96 min; IR (KBr) *v*_{max} 3349, 3201, 3164, 3123 (NH), 2996 (CH_{Ar}), 1637, 1533 (C=C, C=N), 1386, 1133 (SO₂); ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.36 (s, 3H, CH₃), 3.49 (s, 3H, CH₃-N), 4.82 (s, 2H, CH₂), 7.28 (d, 1H, H-4 imidazole), 7.38 (d, 1H, H-5 imidazole), 7.40 (d, 1H, arom.), 7.45–7.56 (m, 3H, arom.), 7.73 (s, 1H, H-3 arom), 7.85 (d, 1H, arom.), 7.92 (d, 1H, arom.), 7.97 (s, 1H, H-6 arom.), 8.14 (d, 1H, arom.), 8.76 (s, 1H, NH), 11.18 (s, 1H, NHSO₂) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.70, 35.10, 35.22, 114.96, 120.97, 124.65, 126.09, 126.60, 126.80, 128.47, 128.98, 129.08, 129.24, 131.30, 131.94, 132.25, 133.03, 134.11, 137.15, 137.96, 138.43, 151.42, 162.34 ppm. Found: C, 53.62; H, 4.21; N, 11.11. Calc. for C₂₃H₂₁ClN₄O₂S₃: C, 53.42; H, 4.09; N, 10.84%.

4-Chloro-2-ethoxycarbonylmethylthio-N-[imino(3-methyl-2-thioxo-2,3-dihydro-1H-imidazol-1-yl)methyl]-5-methylbenzenesulfonamide (14)

Method A. Starting from 7 (0.508 g), 1-methyl-1H-imidazole-2-thiol (0.171 g) and PTSA (0.285 g) in toluene for 15 h, the title compound 14 was obtained (0.076 g, 11%): m.p. 125–126 °C; HPLC (purity 97.93%): *t*_R = 33.06 min; IR (KBr) *v*_{max} 3341, 3208, 3129 (NH), 2960 (CH₃, CH₂), 1722 (C=O), 1647, 1627, 1560 (C=N, C=C), 1345, 1145 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.10 (t, 3H, CH₃), 2.35 (s, 3H, CH₃), 3.48 (s, 3H, CH₃-N), 4.01–4.05 (m, 4H, O-CH₂, S-CH₂), 7.35 (d, 1H, H-4 imidazole), 7.52 (s, 1H, H-3 arom.), 7.59 (d, 1H, H-5 imidazole), 7.96 (s, 1H, H-6), 8.84 (s, 1H, NH), 11.27 (s, 1H, SO₂NH) ppm; ¹³C NMR (150.9 MHz, DMSO-*d*₆) δ 14.39, 19.43, 34.63, 34.99, 61.56, 115.10, 120.85, 128.54, 131.21, 133.22, 135.38, 137.95, 138.16, 151.23, 162.21, 169.23 ppm. Found: C, 41.45; H, 4.09; N, 12.02. Calc. for C₁₆H₁₉ClN₄O₄S₃: C, 41.51; H, 4.14; N, 12.10%.

2-Benzylthio-4-chloro-5-methyl-N-[imino(4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl]benzenesulfonamide (15)

Method A. Starting from 1 (0.580 g), 4-methyl-4H-1,2,4-triazole-3-thiol (0.173 g) and PTSA (0.285 g) in toluene for 28 h, the title compound 15 was obtained (0.239 g, 34%): m.p. 167–170 °C; HPLC (purity 94.05%): *t*_R = 31.42 min; IR (KBr) *v*_{max} 3383 (NH), 3087, 3064 (CH_{Ar}), 2921 (CH₃, CH₂), 1650, 1557 (C=N, C=C), 1356, 1138 (SO₂) cm⁻¹; ¹H NMR (200 MHz, DMSO-*d*₆) δ 2.36 (s, 3H, CH₃), 3.50 (s, 3H, CH₃-N), 4.32 (s, 2H, CH₂), 7.19–7.31 (m, 5H, arom.), 7.58 (s, 1H, H-3 arom.), 7.97 (s, 1H, H-6 arom.), 8.74 (s, 2H, NH and H-5 triazole), 10.25 (s, 1H, SO₂NH) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.41, 32.91, 36.89, 127.64, 128.79, 129.34, 131.06, 133.08, 136.21, 136.69, 137.94, 138.50, 143.37, 151.03, 167.79 ppm. Found: C, 45.98; H, 3.62; N, 14.73. Calc. for C₁₈H₁₈ClN₅O₂S₃: C, 46.19; H, 3.88; N, 14.96%.

4-Chloro-*N*-[imin(4-methyl-5-thioxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)methyl]-5-methyl-2-(3-trifluoromethylbenzylthio)benzenesulfonamide (16)

Method B. Starting from **2** (0.688 g), 4-methyl-4*H*-1,2,4-triazole-3-thiol (0.173 g) and PTSA (0.285 g) in *p*-dioxane for 5 h, the title compound **16** was obtained (0.386 g, 48%): m.p. 170–173 °C; HPLC (purity 97.51%): $t_R = 32.15$ min; IR (KBr) ν_{\max} 3363 (NH), 2924, 2853 (CH₃, CH₂), 1649, 1542 (C=N, C=C), 1331, 1134 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.32 (s, 1H, CH₃), 3.48 (s, 3H, CH₃-N), 4.44 (s, 2H, CH₂), 7.44 (t, 1H, arom.), 7.54–7.59 (m, 2H, arom.), 7.61 (d, 1H, arom.), 7.68 (s, 1H, arom.), 7.98 (s, 1H, H-6 arom.), 8.73 (s, 1H, H-5 triazole), 8.76 (s, 1H, NH), 10.22 (s, 1H, SO₂NH) ppm; ¹³C NMR (150.9 MHz, DMSO-*d*₆) δ 19.41, 32.89, 36.17, 123.63, 124.38, 124.41, 125.43, 126.05, 126.08, 129.84, 129.91, 131.19, 133.44, 133.53, 135.26, 137.94, 138.58, 138.89, 143.41, 150.99, 167.83 ppm. Found: C, 42.46; H, 3.16; N, 13.01. Calc. for C₁₉H₁₇ClF₃N₅O₂S₃: C, 42.57; H, 3.20; N, 13.07%.

4-Chloro-*N*-[imino(4-methyl-5-thioxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)methyl]-5-methyl-2-(4-trifluoromethylbenzylthio)benzenesulfonamide (17)

Method D. Starting from **3** (0.688 g), 4-methyl-4*H*-1,2,4-triazole-3-thiol (0.173 g) and PTSA (0.285 g) in *p*-dioxane for 7 h, after purification on silica gel using CHCl₃/MeOH (*v/v* = 8:1) as the eluent, the title compound **17** was obtained (0.338 g, 42%): m.p. 188.8–190.3 °C; HPLC (purity 98.65%): $t_R = 32.31$ min; IR (KBr) ν_{\max} 3380, (NH), 3088, 3066 (CH_{Ar}), 2924, 2854 (CH₃, CH₂), 1654, 1559 (C=N, C=C), 1344, 1137 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.33 (s, 1H, CH₃), 3.49 (s, 3H, CH₃-N), 4.44 (s, 2H, CH₂), 7.53 (d, 2H, arom.), 7.57 (d, 3H, arom.), 7.97 (s, 1H, H-6 arom.), 8.75 (s, 2H, NH and H-5 triazole), 10.22 (s, 1H, SO₂NH) ppm; ¹³C NMR (150.9 MHz, DMSO-*d*₆) δ 19.43, 32.91, 36.22, 125.59, 125.61, 125.64, 129.61, 131.14, 131.19, 133.50, 135.42, 138.01, 138.81, 142.05, 143.43, 151.03, 167.83 ppm. Found: C, 42.41; H, 3.13; N, 13.05. Calc. for C₁₉H₁₇ClF₃N₅O₂S₃: C, 42.57; H, 3.20; N, 13.07%.

4-Chloro-2-(4-chlorobenzylthio)-*N*-[imino(4-methyl-5-thioxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)methyl]5-methylbenzenesulfonamide (18)

Method D. Starting from **4** (0.638 g), 4-methyl-4*H*-1,2,4-triazole-3-thiol (0.173 g) and PTSA (0.285 g) in *p*-dioxane for 1.5 h, after purification on silica gel using CHCl₃/MeOH (*v/v* = 8:1) as the eluent, the title compound **18** was obtained (0.249 g, 33%): m.p. 184.8–185.7 °C; HPLC (purity 98.75%): $t_R = 32.33$ min; IR (KBr) ν_{\max} 3379, (NH), 3085, 3066 (CH_{Ar}), 2924, 2854 (CH₃, CH₂), 1652, 1557 (C=N, C=C), 1345, 1137 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.33 (s, 1H, CH₃), 3.49 (s, 3H, CH₃-N), 4.33 (s, 2H, CH₂), 7.26 (d, *J* = 8.3 Hz, 2H, arom.), 7.32 (d, *J* = 8.3 Hz, 2H, arom.), 7.57 (s, 1H, H-3 arom.), 7.96 (s, 1H, H-6 arom.), 8.73 (s, 1H, NH), 8.75 (s, 1H, H-5 triazole), 10.22 (s, 1H, SO₂NH) ppm; ¹³C NMR (150.9 MHz, DMSO-*d*₆) δ 19.43, 32.94, 36.04, 128.74, 129.53, 131.13, 132.20, 133.31, 135.74, 136.04, 137.97, 138.73, 143.40, 151.02, 167.81 ppm. Found: C, 42.89; H, 3.35; N, 13.88. Calc. for C₁₉H₁₇ClF₃N₅O₂S₃: C, 43.03; H, 3.41; N, 13.94%.

2-Benzylthio-4-chloro-5-methyl-*N*-[imino(2-thioxo-2,3-dihydro-1*H*-benzo[d]imidazol-1-yl)methyl]benzenesulfonamide (19)

Method C. Starting from **1** (0.580 g), 1*H*-benzo[d]imidazole-2-thiol (0.225 g) and PTSA (0.285 g) in toluene for 14 h, the title compound **19** was obtained (0.228 g, 30%): m.p. 182–185 °C; HPLC (purity 91.23%): $t_R = 33.69$ min; IR (KBr) ν_{\max} 3343 (NH), 3053 (CH_{Ar}), 1630, 1546 (C=N, C=C), 1342, 1138 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.35 (s, 3H, CH₃), 4.34 (s, 2H, CH₂), 7.12–7.18 (m, 2H, arom.), 7.24–7.33 (m, 6H, arom.), 7.59 (s, 1H, H-3 arom.), 7.89 (d, 1H, arom.), 8.04 (s, 1H, H-6 arom.), 8.82 (s, 1H, NH), 10.50 (s, 1H, SO₂NH), 13.65 (s, 1H, NH benzimidazole) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.41, 36.59, 110.49, 115.62, 122.76, 123.71, 125.57, 127.72, 128.31, 128.76, 129.39, 131.10, 131.57, 132.74, 136.35, 136.72, 137.27, 138.30, 152.46, 168.78 ppm. Found: C, 52.90; H, 4.10; N, 11.52. Calc. for C₂₂H₁₉ClN₄O₂S₃: C, 52.53; H, 3.81; N, 11.14%.

4-Chloro-*N*-[imino(2-thioxo-2,3-dihydro-1*H*-benzo[d]imidazol-1-yl)methyl]-5-methyl-2-(3-trifluoromethylbenzylthio)benzenesulfonamide (20)

Method D. Starting from **2** (0.688 g), 1*H*-benzo[d]imidazole-2-thiol (0.225 g) and PTSA (0.285 g) in *p*-dioxane for 6 h, the title compound **20** was obtained (0.428 g, 50%): m.p.

168–172 °C; HPLC (purity 94.55%): $t_R = 34.05$ min; IR (KBr) ν_{\max} 3365, 3228 (NH), 2932 (CH), 1633, 1545 (C=N, C=C), 1329, 1129 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.33 (s, 3H, CH₃), 4.56 (s, 2H, CH₂), 7.11 (t, 1H, arom.), 7.20–7.28 (m, 2H, arom.), 7.35 (t, 1H, arom.), 7.75 (d, 1H, arom.), 7.56 (d, 1H, arom.), 7.58 (s, 1H, H-3 arom.), 7.63 (s, 1H, arom.), 7.86 (s, 1H, arom.), 8.03 (s, 1H, H-6 arom.), 8.83 (s, 1H, NH), 10.45 (s, 1H, SO₂NH), 13.63 (s, 1H, NH benzimidazole) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.64, 36.09, 110.74, 115.70, 123.85, 124.69, 125.75, 126.26, 128.96, 129.60, 130.04, 131.35, 131.89, 133.38, 133.70, 136.07, 137.83, 138.47, 138.54, 152.66, 169.02 ppm. Found: C, 48.08; H, 3.13; N, 9.64. Calc. for C₂₃H₁₈ClF₃N₄O₂S₃: C, 48.37; H, 3.18; N, 9.81%.

4-Chloro-*N*-[imino-(2-thioxo-2,3-dihydro-1*H*-benzo[*d*]imidazol-1-yl)methyl]-5-methyl-2-(4-trifluoromethylbenzylthio)benzenesulfonamide (21)

Method D. Starting from 3 (0.688 g), 1*H*-benzo[*d*]imidazole-2-thiol (0.225 g) and PTSA (0.285 g) in *p*-dioxane for 4 h, the title compound 21 was obtained (0.428 g, 50%): m.p. 188–189 °C; HPLC (purity 95.68%): $t_R = 34.08$ min; IR (KBr) ν_{\max} 3363, (NH), 3027 (CH_{Ar}), 2860 (CH₃, CH₂), 1648, 1585 (C=N, C=C), 1323, 1155 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.33 (s, 3H, CH₃), 4.45 (s, 2H, CH₂), 7.10 (t, 1H, arom.), 7.23 (d, 1H, arom.), 7.28 (t, 1H, arom.), 7.44 (d, 2H, arom.), 7.46 (d, 2H, arom.), 7.60 (s, 1H, H-3 arom.), 7.83 (d, 1H, arom.), 8.02 (s, 1H, H-6 arom.), 8.83 (s, 1H, NH), 10.50 (s, 1H, SO₂NH), 13.65 (s, 1H, NH benzimidazole) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.66, 36.06, 110.74, 115.79, 123.92, 125.78, 128.84, 130.29, 131.33, 131.83, 133.40, 136.05, 137.91, 138.57, 142.01, 152.70, 169.01 ppm. Found: C, 47.99; H, 3.05; N, 9.53. Calc. for C₂₃H₁₈ClF₃N₄O₂S₃: C, 48.37; H, 3.18; N, 9.81%.

4-Chloro-2-(4-chlorobenzylthio)-*N*-[imino-(2-thioxo-2,3-dihydro-1*H*-benzo[*d*]imidazol-1-yl)methyl]-5-methylbenzenesulfonamide (22)

Method D. Starting from 4 (0.638 g), 1*H*-benzo[*d*]imidazole-2-thiol (0.225 g) and PTSA (0.285 g) in *p*-dioxane for 4.5 h, the title compound 22 was obtained (0.322 g, 40%): m.p. 181.8–183.5 °C; HPLC (purity 94.42%): $t_R = 34.28$ min; IR (KBr) ν_{\max} 3386, 3186 (NH), 3081, 3038 (CH_{Ar}), 2922, 2856 (CH₃, CH₂), 1639, 1543 (C=N, C=C), 1345, 1137 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.33 (s, 3H, CH₃), 4.33 (s, 2H, CH₂), 7.08–7.18 (m, 3H, arom.), 7.22–7.27 (m, 3H, arom.), 7.29 (t, 1H, arom.), 7.58 (s, 1H, H-3 arom.), 7.84 (d, 1H, arom.), 8.02 (s, 1H, H-6 arom.), 8.81 (s, 1H, NH), 10.50 (s, 1H, SO₂NH), 13.65 (s, 1H, NH benzimidazole) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.66, 35.94, 110.75, 115.82, 123.94, 125.82, 128.79, 128.91, 131.34, 131.81, 132.49, 133.23, 135.97, 136.40, 137.79, 138.54, 152.68, 169.00 ppm. Found: C, 48.78; H, 3.36; N, 10.03. Calc. for C₂₂H₁₈Cl₂N₄O₂S₃: C, 49.19; H, 3.38; N, 10.42%.

4-Chloro-2-(6-chlorobenzylthio)-[1,3]dioxol-5-ylmethylthio)-*N*-[imino-(2-thioxo-2,3-dihydro-1*H*-benzo[*d*]imidazol-1-yl)methyl]-5-methylbenzenesulfonamide (23)

Method D. Starting from 5 (0.638 g), 1*H*-benzo[*d*]imidazole-2-thiol (0.225 g) and PTSA (0.285 g) in *p*-dioxane for 6 h, the title compound 23 was obtained (0.358 g, 41%): m.p. 213–214 °C; HPLC (purity 92.21%): $t_R = 34.16$ min; IR (KBr) ν_{\max} 3367, 3262 (NH), 2975, 2847 (CH), 1627, 1505 (C=N, C=C), 1342, 1137 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.36 (s, 3H, CH₃), 4.26 (s, 2H, CH₂), 6.00 (s, 2H, CH₂-O), 6.84 (d, 2H, arom.), 7.05 (t, 1H, arom.), 7.18–7.28 (m, 2H, arom.), 7.59 (s, 1H, H-3 arom.), 7.77 (d, 1H, arom.), 8.04 (s, 1H, H-6 arom.), 8.78 (s, 1H, NH), 10.56 (s, 1H, SO₂NH), 13.63 (s, 1H, NH benzimidazole) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.70, 35.35, 67.04, 102.76, 110.06, 110.66, 110.88, 115.98, 123.83, 125.76, 127.03, 128.99, 131.28, 131.81, 133.38, 136.61, 137.93, 138.59, 147.15, 148.22, 152.81, 169.00 ppm. Found: C, 47.39; H, 3.17; N, 9.30. Calc. for C₂₃H₁₈Cl₂N₄O₄S₃: C, 47.50; H, 3.12; N, 9.63%.

4-Chloro-*N*-[imino-(2-thioxo-2,3-dihydro-1*H*-benzo[*d*]imidazol-1-yl)methyl]-5-methyl-2-(naphthalen-1-ylmethylthio)benzenesulfonamide (24)

Method D. Starting from 6 (0.638 g), 1*H*-benzo[*d*]imidazole-2-thiol (0.225 g) and PTSA (0.285 g) in *p*-dioxane for 6.5 h, the title compound 24 was obtained (0.456 g, 55%): m.p. 192–193 °C; HPLC (purity 92.14%): $t_R = 34.77$ min; IR (KBr) ν_{\max} 3479, 3363 (NH), 3053 (CH_{Ar}), 1630, 1546 (C=N, C=C), 1342, 1138 (SO₂) cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.37 (s, 3H, CH₃), 4.79 (s, 2H, CH₂), 6.91 (d, 1H, arom.), 7.18–7.26 (m, 2H, arom.), 7.30–7.36

(m, 2H, arom.), 7.42 (d, 1H, arom.), 7.45 (d, 1H, arom.), 7.67 (d, 1H, arom.), 7.74 (s, 1H, H-3 arom.), 7.80 (d, 1H, arom.), 7.86 (d, 1H, arom.), 8.06 (s, 1H, H-6 arom.), 8.09 (d, 1H, arom.), 8.78 (s, 1H, NH), 10.40 (s, 1H, SO₂NH), 13.58 (s, 1H, NH benzimidazole) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆) δ 19.70, 35.13, 110.66, 115.53, 123.84, 124.69, 125.67, 126.00, 126.54, 126.73, 128.53, 128.96, 129.05, 129.13, 131.25, 131.27, 131.75, 131.91, 132.09, 133.14, 134.01, 137.33, 137.57, 138.65, 152.59, 168.92 ppm. Found: C, 56.29; H, 4.00; N, 9.90. Calc. for C₂₆H₂₁ClN₄O₂S₃: C, 56.46; H, 3.83; N, 10.13%.

3.2. X-ray Structure Determination

The diffraction intensity data were collected on an IPDS 2T dual-beam diffractometer (STOE & Cie GmbH, Darmstadt, Germany) at 120.0(2) K with CuK α radiation from a microfocus X-ray source (GeniX 3D Cu High Flux, Xenocs, Sassenage, 50 kV, 0.6 mA, $\lambda = 1.54186$ Å). The crystal was thermostated in a nitrogen stream at 120 K using the CryoStream-800 device (Oxford CryoSystem, Long Hanborough, UK) during the entire experiment.

Data collection and data reduction were controlled by the X-Area 1.75 program (STOE, 2015). An absorption correction was performed on the integrated reflections by a combination of frame scaling, reflection scaling and a spherical absorption correction. Outliers were rejected according to the Blessing's method. The structures were solved by direct methods and refined anisotropically using the program packages OLEX2 and SHELX-2015. The positions of the C-H hydrogen atoms were calculated geometrically and taken into account with isotropic temperature factors. The amine hydrogen atoms H2a and H2b were found in the Fourier residual electron density map and were refined with the N-H distance restrained to 0.88(2) Å.

Computer programs: X-Area WinXpose 2.0.22.0 (STOE, 2016), X-Area Recipe 1.33.0.0 (STOE, 2015), STOE X-Area, ShelXT [48], SHELXL [49], Olex2 [50].

The crystal data, data collection and structure refinement details are summarized in Tables S1–S2.

Crystallographic data for the structure of **10** reported in this paper were deposited in the Cambridge Crystallographic Data Centre as a supplementary publication, No. CCDC 1832901. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: (p44) 1223-336-033; Email: deposit@ccdc.cam.ac.uk).

3.3. Cell Culture and Cell Viability Assay

All chemicals, if not stated otherwise, were obtained from Sigma-Aldrich (St. Louis, MO, USA). The MCF-7, HeLa and HaCaT cell lines were purchased from Cell Lines Services (Eppelheim, Germany), and the HCT-116 cell line was purchased from ATCC (ATCC-No: CCL-247). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/mL of penicillin and 100 μ g/mL of streptomycin. The cultures were maintained in a humidified atmosphere with 5% CO₂ at 37 °C, in an incubator (Heraeus, HeraCell).

Cytotoxicity assay: Cell viability was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay. The cells were seeded in 96-well plates at a density of 5×10^3 cells/well and treated for 24, 48 and 72 h with the examined compounds in the concentration range 1–100 μ M. Following treatment, MTT (0.5 mg/mL) was added to the medium, and the cells were further incubated for 2 h at 37 °C. The cells were lysed with DMSO, and the absorbance of the formazan solution was measured at 550 nm with a plate reader (Victor, 1420 multilabel counter). The experiment was performed in triplicate. The values are expressed as the mean \pm SD of at least three independent experiments.

Detection of apoptosis by Annexin V-PE and 7-AAD staining: Apoptosis induction was detected with an Annexin V-PE Apoptosis Detection Kit I (BD Biosciences, Belgium) according to the manufacturer's instructions. The cells were treated with **11–13** (2.5, 5 and 10 μ M) for 24 and 48 h. Following treatment, the cells were collected and stained with Annexin V-phycoerythrin (PE) and 7-amino-actinomycin (7-AAD) in Annexin-binding

buffer for 15 min at RT in the dark. The acquisition was performed on a FACSCalibur cytometer (BD), and the data were analyzed with Flowing software (version 2.5).

Caspase Activity Determination: Caspase activity was determined with the FLICA Apoptosis Detection Kit (Immunochemistry Technologies) according to the manufacturer's instructions. The cells were treated with comp. **11**, **12** and **13** (5, 7 and 10 μM) for 24 h, after which the cells were collected and suspended in a buffer containing the caspase inhibitor, i.e., a carboxyfluorescein-labeled fluoromethyl ketone peptide. The cells were subsequently incubated for 1 h at 37 $^{\circ}\text{C}$ under 5% CO_2 and, next, they were washed with a washing buffer. The fluorescence intensity of fluorescein was determined by flow cytometry (BD FACSCalibur), and caspase activity was determined as the amount of fluorescence emitted from the caspase inhibitors bound to the caspases. The data were analyzed with Flowing software (version 2.5).

Cell Cycle Distribution Analysis: The effects of **11**, **12** and **13** on the cell cycle distribution in HeLa cells were determined by flow cytometry analysis. The cells were treated with **11**, **12** and **13** (5, 7 and 10 μM) for 48 h, after which they were fixed in cold 70% ethanol for 24 h. The fixed cells were treated with 100 $\mu\text{g}/\text{mL}$ of RNase (Invitrogen, Germany) and stained with 10 $\mu\text{g}/\text{mL}$ of PI (Invitrogen, Germany) for 30 min at RT. The acquisition was performed on a FACSCalibur cytometer (BD), and the data were analyzed with Flowing software (version 2.5).

Statistical Analysis: Values are expressed as means \pm SD of at least three independent experiments. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad software). Differences between control and treated samples were analyzed by one-way ANOVA with Tukey's post hoc tests. A p -value < 0.05 was considered statistically significant in each experiment.

3.4. In Vitro Metabolic Stability Assay

Stock solutions of the studied compounds were prepared at a concentration of 10 mM in DMSO. Working solutions were prepared by dilution of the stock solutions with reaction buffer or acetonitrile; the final concentration of the organic solvent did not exceed 1%. The incubation mixture contained the studied derivative at a 10 μM concentration, 1 mM NADPH (Sigma-Aldrich) and 0.5 mg/mL of human liver microsomes (HLM, Sigma-Aldrich) in potassium phosphate buffer (0.1 M, pH 7.4). The incubation was carried out in a thermostat at 37 $^{\circ}\text{C}$ and started by the addition of the compound of interest. Then, 20 μL samples were taken after 5, 15, 30, 45 and 60 min. The enzymatic reaction was terminated by the addition of an equal volume of ice-cold acetonitrile containing 10 μM sulfamethoxazole as an internal standard. Control incubations were performed without NADPH as a negative control reflecting NADPH-independent processes, such as chemical degradation and precipitation. After collection, the samples were immediately centrifuged (10 min, 10,000 rpm), and the resulting supernatant was directly analyzed or kept at -80°C until LC-MS analysis. The natural logarithm of a compound over the IS peak area ratio was plotted vs. the incubation time. The metabolic half-time ($t_{1/2}$) was calculated from the slope of the linear regression, as demonstrated [51].

The LC-MS analysis was performed on an Agilent 1260 system coupled to SingleQuad 6120 mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). Poroshell EC-C18 (2.1 mm \times 150 mm, 2.7 μm , Agilent Technologies, Santa Clara, CA, USA) was used in reversed-phase mode with gradient elution starting with 90% of phase A (0.1% formic acid in water) and 10% of phase B (0.1% dormic acid in acetonitrile). The amount of phase B was linearly increased to 100% in 15 min and equilibrated. The total analysis time was 21 min at 25 $^{\circ}\text{C}$, the flow rate was 0.5 mL/min, and the injection volume was 20 μL . The mass spectrometer was equipped with an electrospray ion source and operated in positive ionization mode. The mass analyzer was set for each individual compound to detect the $[\text{M}+\text{H}]^+$ protonated molecule. The MSD parameters of the ESI source were as follows: nebulizer pressure 40 psig (N_2), drying gas 10 mL/min (N_2), drying gas temperature 300 $^{\circ}\text{C}$, capillary voltage 3.0 kV, fragmentor voltage 150 V.



4. Conclusions

In conclusion, our study focused on the design and synthesis of novel benzenesulfonamide derivatives containing imidazole rings as potential anticancer agents. The cytotoxic evaluation revealed that compounds **11–13** exhibited remarkable selectivity and efficacy against HeLa cervical cancer cells, with IC_{50} values of 6–7 μ M. These compounds showed significantly lower cytotoxicity towards the non-tumor cell line HaCaT (IC_{50} : 18–20 μ M). The enhanced anticancer activity of compounds **11–13** was further supported by their ability to induce apoptosis, as demonstrated by increased phosphatidylserine externalization, caspase activation, and DNA fragmentation. Additionally, an in vitro metabolic stability assay suggested potential oxidation pathways for these compounds. These findings highlight the potential of benzenesulfonamide–imidazole hybrids as promising candidates for the development of new and effective anticancer agents. However, further research is necessary to optimize their design, enhance their efficacy and ensure their safety.

Supplementary Materials: The supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms24119768/s1>.

Author Contributions: B.Ż. and J.S. created the concept and designed the study; B.Ż. performed the synthesis of the compounds; B.Ż., J.S. and A.K. wrote the manuscript; A.K. tested the cytotoxic activity toward the HCT-116, MCF-7, HeLa and HaCaT cell lines of all obtained compounds and performed the studies on their apoptotic activity; J.C. performed the crystallographic analysis; M.B. and T.B. performed the metabolic stability analysis; M.B. performed the HPLC analysis. All the authors discussed the results of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by the Medical University of Gdansk under the “Excellence Initiative—Research University” program.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are available as Supplementary Materials.

Acknowledgments: Acknowledgments to Andrzej Zięba from the Department of Organic Chemistry, Faculty of Pharmaceutical Sciences, in Sosnowiec, Medical University of Silesia, Sosnowiec, Poland, for performing the spectroscopic analysis ^{13}C NMR.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M. *Global Cancer Observatory: Cancer Today*; International Agency for Research on Cancer: Lyon, France, 2020; Available online: <https://gco.iarc.fr/today> (accessed on 9 May 2023).
2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. [[CrossRef](#)] [[PubMed](#)]
3. Barreca, M.; Ingarrà, A.M.; Raimondi, M.V.; Spanò, V.; Piccionello, A.P.; De Franco, M.; Menilli, L.; Gandin, V.; Miolo, G.; Barreja, P.; et al. New tricyclic systems as photosensitizers towards triple negative breast cancer cells. *Arch. Pharmacol. Res.* **2022**, *45*, 806–821. [[CrossRef](#)]
4. Liu, J.; Zhu, X.; Yu, L.; Mao, M. Discovery of novel sulphonamide hybrids that inhibit LSD1 against bladder cancer cells. *J. Enzym. Inhib. Med. Chem.* **2022**, *37*, 866–875. [[CrossRef](#)] [[PubMed](#)]
5. AL-Ghulikah, H.A.; El-Sebaey, S.A.; Bass, A.K.A.; El-Zoghbi, M.S. New Pyrimidine-5-Carbonitriles as COX-2 Inhibitors: Design, Synthesis, Anticancer Screening, Molecular Docking, and In Silico ADME Profile Studies. *Molecules* **2022**, *27*, 7485. [[CrossRef](#)]
6. Grillone, K.; Riillo, C.; Rocca, R.; Ascrizzi, S.; Spanò, V.; Scionti, F.; Polera, N.; Maruca, A.; Barreca, M.; Juli, G.; et al. The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma. *Int. J. Mol. Sci.* **2022**, *23*, 10222. [[CrossRef](#)] [[PubMed](#)]
7. Fortin, S.; Bérubé, G. Advances in the development of hybrid anticancer drugs. *Expert Opin. Drug Discov.* **2013**, *8*, 1029–1047. [[CrossRef](#)]
8. Nepali, K.; Sharma, S.; Sharma, M.; Bedi, P.M.; Dhar, K.L. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. *Eur. J. Med. Chem.* **2014**, *77*, 422–487. [[CrossRef](#)]

9. Kleczkowska, P.; Kowalczyk, A.; Lesniak, A.; Bujalska-Zadrozny, M. The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980–Present). *Curr. Top. Med. Chem.* **2017**, *17*, 875–894. [[CrossRef](#)]
10. Kleczkowska, P. Chimeric Structures in Mental Illnesses—“Magic” Molecules Specified for Complex Disorders. *Int. J. Mol. Sci.* **2022**, *23*, 3739. [[CrossRef](#)]
11. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. *J. Med. Chem.* **2005**, *48*, 6523–6543. [[CrossRef](#)]
12. Fujii, H. Twin and Triplet Drugs in Opioid Research. In *Chemistry of Opioids; Topics in Current Chemistry*; Nagase, H., Ed.; Springer: Berlin/Heidelberg, Germany, 2010; pp. 239–275.
13. Abdolmaleki, A.; Ghasemi, J.B. Dual-acting of hybrid compounds—A new dawn in the discovery of multi-target drugs: Lead generation approaches. *Curr. Top. Med. Chem.* **2017**, *17*, 1096–1114. [[CrossRef](#)] [[PubMed](#)]
14. Qingjie, Z.; Guozheng, H. Anticancer Hybrids. In *Design of Hybrid Molecules for Drug Development*; Decker, M., Ed.; Elsevier: Amsterdam, The Netherlands, 2017; pp. 193–218.
15. Nagaraju, K.; Lalitha, G.; Suresh, M.; Kranthi, K.G.; Sreekantha, B.J. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. *Molecules* **2020**, *25*, 1909.
16. Ali, I.; Lone, M.N.; Aboul-Enein, H.Y. Imidazoles as potential anticancer agents. *Med. Chem. Commun.* **2017**, *8*, 1742–1773. [[CrossRef](#)]
17. Rani, N.; Sharma, A.; Singh, R. Imidazoles as promising scaffolds for antibacterial activity: A review. *Mini Rev. Med. Chem.* **2013**, *13*, 1812–1835. [[CrossRef](#)] [[PubMed](#)]
18. Zhan, P.; Liu, X.; Zhu, J.; Fang, Z.; Li, Z.; Pannecouque, C.; de Clercq, E. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorg. Med. Chem.* **2009**, *17*, 5775–5781. [[CrossRef](#)] [[PubMed](#)]
19. Mishra, R.; Ganguly, S. Imidazole as an anti-epileptic: An overview. *Med. Chem. Res.* **2012**, *21*, 3929–3939. [[CrossRef](#)]
20. Fan, Y.L.; Jin, X.H.; Huang, Z.P.; Yu, H.F.; Zeng, Z.G.; Gao, T.; Feng, L.S. Recent advances of imidazole-containing derivatives as anti-tubercular agents. *Eur. J. Med. Chem.* **2018**, *150*, 347–365. [[CrossRef](#)]
21. Rani, N.; Sharma, A.; Gupta, G.K.; Singh, R. Imidazoles as potential antifungal agents: A review. *Mini Rev. Med. Chem.* **2013**, *13*, 1626–1655. [[CrossRef](#)]
22. Meng, L.; Zhao, P.; Hu, Z.; Ma, W.; Niu, Y.; Su, J.; Zhang, Y. Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer. *Anticancer Agents Med. Chem.* **2022**, *22*, 596–602. [[CrossRef](#)]
23. Amatu, A.; Sartore-Bianchi, A.; Moutinho, C.; Belotti, A.; Bencardino, K.; Chirico, G.; Cassingena, A.; Rusconi, F.; Esposito, A.; Nichelatti, M.; et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. *Clin. Cancer Res.* **2015**, *19*, 2265–2272. [[CrossRef](#)]
24. Moulin, A.; Bibian, M.; Blayo, A.L.; El Habnoui, S.; Martinez, J.; Fehrentz, J.A. Synthesis of 3,4,5-trisubstituted-1,2,4-triazoles. *Chem. Rev.* **2010**, *110*, 1809–1827. [[CrossRef](#)]
25. Gupta, D.; Jain, D.K. Synthesis, antifungal and antibacterial activity of novel 1,2,4-triazole derivatives. *J. Adv. Pharm. Technol. Res.* **2015**, *6*, 141–146. [[CrossRef](#)] [[PubMed](#)]
26. Sarigol, D.; Uzgoren-Baran, A.; Tel, B.C.; Somuncuoglu, E.I.; Kazkayasi, I.; Ozadali-Sari, K.; Unsal-Tan, O.; Okay, G.; Ertan, M.; Tozkoparan, B. Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies. *Bioorg. Med. Chem.* **2015**, *23*, 2518–2528. [[CrossRef](#)] [[PubMed](#)]
27. Karczmarzyk, Z.; Swatko-Ossor, M.; Wysocki, W.; Drozd, M.; Ginalska, G.; Pachuta-Stec, A.; Pitucha, M. New Application of 1,2,4-Triazole Derivatives as Antitubercular Agents. Structure, In Vitro Screening and Docking Studies. *Molecules* **2020**, *25*, 6033. [[CrossRef](#)] [[PubMed](#)]
28. El-Sebaey, S.A. Recent Advances in 1,2,4-Triazole Scaffolds as Antiviral Agents. *ChemistrySelect* **2020**, *5*, 11654–11680. [[CrossRef](#)]
29. Azim, T.; Wasim, M.; Akhtar, M.S.; Akram, I. An in vivo evaluation of anti-inflammatory, analgesic and anti-pyretic activities of newly synthesized 1,2,4 Triazole derivatives. *BMC Complement. Med. Ther.* **2021**, *21*, 304. [[CrossRef](#)] [[PubMed](#)]
30. Ramandeep, K.; Ashish, D.R.; Bhupinder, K.; Vinod, K. Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review. *Anticancer Agents Med. Chem.* **2016**, *16*, 465–489.
31. Chumsri, S. Clinical utilities of aromatase inhibitors in breast cancer. *Int. J. Womens Health* **2015**, *7*, 493–499. [[CrossRef](#)]
32. Talpaz, M.; Kiladjian, J.J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. *Leukemia* **2021**, *35*, 1–17. [[CrossRef](#)]
33. Kumar, R.; Knick, V.B.; Rudolph, S.K.; Johnson, J.H.; Crosby, R.M.; Crouthamel, M.C.; Hopper, T.M.; Miller, C.G.; Harrington, L.E.; Onori, J.A.; et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. *Mol. Cancer Ther.* **2007**, *6*, 2012–2021. [[CrossRef](#)]
34. Long, G.V.; Hauschild, A.; Santinami, M.; Atkinson, V.; Mandala, M.; Chiarion-Sileni, V.; Larkin, J.; Nyakas, M.; Dutriaux, C.; Haydon, A.; et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N. Engl. J. Med.* **2017**, *377*, 1813–1823. [[CrossRef](#)] [[PubMed](#)]
35. Fisher, R.; Larkin, J. Vemurafenib: A new treatment for BRAF-V600 mutated advanced melanoma. *Cancer Manag. Res.* **2012**, *4*, 243–252. [[PubMed](#)]
36. Guerra, V.A.; DiNardo, C.; Konopleva, M. Venetoclax-based therapies for acute myeloid leukemia. *Best Pract. Res. Clin. Haematol.* **2019**, *32*, 145–153. [[CrossRef](#)] [[PubMed](#)]



37. Mohamad Anuar, N.N.; Nor Hisam, N.S.; Liew, S.L.; Ugusman, A. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent. *Front. Pharmacol.* **2020**, *11*, 564108. [[CrossRef](#)]
38. Meier, T.; Uhlik, M.; Chintharlapalli, S.; Dowless, M.; Van Horn, R.; Stewart, J.; Blosser, W.; Cook, J.; Young, D.; Ye, X.; et al. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. *Mol. Cancer Ther.* **2011**, *10*, 2168–2178. [[CrossRef](#)]
39. Fulda, S. Tumor resistance to apoptosis. *Int. J. Cancer* **2009**, *124*, 511–515. [[CrossRef](#)]
40. Fulda, S. Evasion of apoptosis as a cellular stress response in cancer. *Int. J. Cell Biol.* **2010**, *2010*, 370835. [[CrossRef](#)]
41. Sławiński, J. Syntheses and some reactions of 3-amino-6-chloro-7-methyl-1,1-dioxo-1,4,2-benzodithiazine. *Polish J. Chem.* **2001**, *75*, 1309–1316.
42. Sławiński, J.; Żołnowska, B.; Orlewska, C.; Chojnacki, J. Synthesis and molecular structure of novel 2-(alkylthio)-4-chloro-*N*-(4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-5-methylbenzenesulfonamides with potential anticancer activity. *Mon. Für Chem.* **2012**, *143*, 1705–1718. [[CrossRef](#)]
43. Sławiński, J.; Pogorzelska, A.; Żołnowska, B.; Kędzia, A.; Ziółkowska-Klinkosz, M.; Kwapisz, E. Synthesis and anti-yeast evaluation of novel 2-alkylthio-4-chloro-5-methyl-*N*-[imino-(1-oxo-(1*H*)-phthalazin-2-yl)methyl]benzenesulfonamide derivatives. *Molecules* **2014**, *19*, 13704–13723. [[CrossRef](#)]
44. Żołnowska, B.; Sławiński, J.; Pogorzelska, A.; Chojnacki, J.; Vullo, D.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series *N*-substituted *N'*-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII. *Eur. J. Med. Chem.* **2014**, *17*, 135–147.
45. Zaretski, J.; Matlock, M.; Swamidass, S.J. XenoSite: Accurately Predicting CYP-Mediated Sites of Metabolism with Neural Networks. *J. Chem. Inf. Model.* **2013**, *53*, 3373–3383. [[CrossRef](#)] [[PubMed](#)]
46. Henderson, M.C.; Siddens, L.K.; Krueger, S.K.; Stevens, J.F.; Kedzie, K.; Fang, W.K.; Heidelbaugh, T.; Nguyen, P.; Chow, K.; Garst, M.; et al. Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones. *Toxicol. Appl. Pharmacol.* **2014**, *278*, 91–99. [[CrossRef](#)] [[PubMed](#)]
47. Yamazaki, M.; Shimizu, M.; Uno, Y.; Yamazaki, H. Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. *Biochem. Pharmacol.* **2014**, *90*, 159–165. [[CrossRef](#)] [[PubMed](#)]
48. Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. *Acta Crystallogr.* **2015**, *A71*, 3–8. [[CrossRef](#)] [[PubMed](#)]
49. Sheldrick, G.M. Crystal structure refinement with SHELXL. *Acta Crystallogr.* **2015**, *C71*, 3–8.
50. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* **2009**, *42*, 339–341. [[CrossRef](#)]
51. Obach, R.S. Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes. *Drug Metab. Dispos.* **1999**, *27*, 1350–1359.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

